ChiCTR2600125196 版本V1.0 版本创建时间2026/05/22 09:56:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600125196 

最近更新日期:

Date of Last Refreshed on:

2026-05-22 09:56:24 

注册时间:

Date of Registration:

2026-05-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于三阴性乳腺癌精准分型的肿瘤血管生成模式研究

Public title:

Study on tumour angiogenesis pattern based on precise typing of triple-negative breast cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于三阴性乳腺癌精准分型的肿瘤血管生成模式研究

Scientific title:

Study on tumour angiogenesis pattern based on precise typing of triple-negative breast cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

董丹凤 

研究负责人:

董丹凤 

Applicant:

Dong Danfeng 

Study leader:

Dong Danfeng 

申请注册联系人电话:

Applicant telephone:

+86 15349257340

研究负责人电话:

Study leader's
telephone:

+86 29 85323215

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qiwudanfeng@163.com

研究负责人电子邮件:

Study leader's E-mail:

qiwudanfeng@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国陕西省西安市雁塔区雁塔西路277号

研究负责人通讯地址:

中国陕西省西安市雁塔区雁塔西路277号

Applicant address:

277 West Yanta Road, Yanta District, Xi’an, Shaanxi, China

Study leader's address:

277 West Yanta Road, Yanta District, Xi’an, Shaanxi, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西安交通大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Xi'an Jiaotong University

研究负责人所在单位:

西安交通大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Xi'an Jiaotong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XJTU1AF2024LSYY-370

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安交通大学第一附属医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Xian Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-12 00:00:00

伦理委员会联系人:

易秋月

Contact Name of the ethic committee:

Yi Qiuyue

伦理委员会联系地址:

中国陕西省西安市雁塔区雁塔西路277号

Contact Address of the ethic committee:

277 West Yanta Road, Yanta District, Xi’an, Shaanxi, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 29 85323473

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yqy0118@163.com

研究实施负责(组长)单位:

西安交通大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Xi'an Jiaotong University

研究实施负责(组长)单位地址:

中国陕西省西安市雁塔区雁塔西路277号

Primary sponsor's address:

277 West Yanta Road, Yanta District, Xi’an, Shaanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第一附属医院

具体地址:

中国陕西省西安市雁塔区雁塔西路277号

Institution
hospital:

The First Affiliated Hospital of Xi'an Jiaotong University

Address:

277 West Yanta Road, Yanta District, Xi’an, Shaanxi, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

三阴性乳腺癌  

Target disease:

Triple-negative breast cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1. 探索不同分子亚型的TNBC血管生成模式; 2. 探究不同的血管生成模式对肿瘤生长的意义。  

Objectives of Study:

1. To explore the angiogenesis patterns of different molecular subtypes of TNBC.; 2. to explore the significance of different angiogenesis patterns for tumour growth.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

三阴性乳腺癌

Inclusion criteria

Triple negative breast cancer

排除标准:

其他类型乳腺癌

Exclusion criteria:

Other types of breast cancer

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-27 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

120

Group:

Observational group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肿瘤血管形成情况

指标类型:

主要指标

Outcome:

Tumor angiogenesis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者预后

指标类型:

主要指标

Outcome:

Patient prognosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床病理特征

指标类型:

次要指标

Outcome:

Clinical pathological characteristics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age NA years
最大 Max age NA years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Collection Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-22 09:56:24